AlphaCore Capital LLC Has $1.16 Million Stock Holdings in Neumora Therapeutics, Inc. $NMRA

AlphaCore Capital LLC increased its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 89.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 638,784 shares of the company’s stock after acquiring an additional 301,017 shares during the quarter. AlphaCore Capital LLC owned about 0.38% of Neumora Therapeutics worth $1,163,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Legacy Private Trust Co. bought a new position in Neumora Therapeutics during the 3rd quarter worth approximately $25,000. Brookstone Capital Management bought a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at $42,000. CWM LLC increased its position in shares of Neumora Therapeutics by 41.8% during the second quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after buying an additional 10,537 shares during the period. Catalyst Funds Management Pty Ltd bought a new position in Neumora Therapeutics during the second quarter worth $29,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Neumora Therapeutics in the second quarter valued at $41,000. 47.65% of the stock is currently owned by institutional investors.

Insider Activity at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total transaction of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. This trade represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 23,387 shares of company stock valued at $82,647 in the last three months. Corporate insiders own 26.80% of the company’s stock.

Neumora Therapeutics Trading Up 2.6%

NASDAQ NMRA opened at $3.55 on Friday. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.13. Neumora Therapeutics, Inc. has a 12 month low of $0.61 and a 12 month high of $3.65. The firm has a market capitalization of $593.17 million, a P/E ratio of -2.41 and a beta of 3.20.

Analyst Ratings Changes

NMRA has been the topic of a number of research analyst reports. Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a research report on Monday, January 5th. Stifel Nicolaus upped their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Leerink Partners assumed coverage on Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 target price for the company. Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $4.00 to $7.00 in a report on Monday, December 1st. Finally, William Blair upgraded Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Neumora Therapeutics presently has an average rating of “Hold” and an average target price of $8.13.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.